Sunitinib (Sutent) has been approved as the first anti-VEGF (vascular endothelial growth factor) agent for neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease.
In an article published online on May 9, 2011 in the Journal of Clinical Oncology, a large-scale prospective study found that acetaminophen use was associated with an almost two-fold increase risk of hematological malignancies other than chronic lymphocytic leukemia/small lymphocytic lymphoma.
A retrospective study of metastatic renal cell carcinoma (mRCC) patients published in the journal Cancer found that patients treated with tyrosine kinase inhibitors (TKIs) had better overall survival and less-frequent metastasis to the brain.
For the second year in a row, metastatic melanoma (MM) research will be presented at the plenary session of the American Society of Clinical Oncology (ASCO) Annual meeting.
A study published in the journal Cancer on May 9 has now specifically examined the outcome of cancer survivorship of the gay, lesbian, and bisexual population. The study authors found that cancer outcomes differ based on sexual orientation.
A large-scale, retrospective study published in the JNCI has now shown that men who take statins had lower incidence of total and high-grade prostate cancer compared with men who took antihypertensive medications.
Researchers from Memorial Sloan Kettering Cancer Center and the Weill Medical School of Cornell University have shown an association of epidermal growth factor receptor (EGFR) mutations among tumor samples from men and those who smoke cigarettes.
Following a retrospective analysis which may be the largest of its kind to date, a multicenter team of investigators says treatment-related hypertension may be a useful biomarker of superior clinical outcome with sunitinib (Sutent) in patients with metastatic renal cell carcinoma (RCC).
Gail R. Wilensky, PhD, has written an editorial on the Medicare reform that was published on April 27. 2011 in the online version of the NEJM. Professor Wilensky is an ecomomist, senior fellow at Project HOPE, and serves on Congressional committees to advise Congress on payment and other Medicare-related issues.
On April 28, the FDA announced the approval of abiraterone acetate (Zytiga) in conjunction with a steroid, prednisone, as treatment for late-stage (metastatic) castration-resistant prostate cancer patients who have received prior docetaxel.